Robbie B Mailliard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/239745/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Symptomatic human immunodeficiency virus infection is associated with advanced presentation and perioperative mortality in patients undergoing surgery for peripheral arterial disease. Journal of Vascular Surgery, 2022, 75, 1403-1412.e2.	1.1	3
2	Gut microbiota composition and outcomes following neoadjuvant therapy in patients with localized pancreatic cancer: A prospective biomarker study Journal of Clinical Oncology, 2022, 40, 4143-4143.	1.6	1
3	Elevated HIV Infection of CD4 T Cells in MRKAd5 Vaccine Recipients Due to CD8 T Cells Targeting Adapted Epitopes. Journal of Virology, 2021, 95, e0016021.	3.4	4
4	Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes. EBioMedicine, 2021, 63, 103175.	6.1	10
5	Role of Dendritic Cells in Exposing Latent HIV-1 for the Kill. Viruses, 2020, 12, 37.	3.3	11
6	Dendritic Cells and Antiviral Defense. Viruses, 2020, 12, 1152.	3.3	2
7	IL-18 Responsiveness Defines Limitations in Immune Help for Specialized FcRγ–NK Cells. Journal of Immunology, 2020, 205, 3429-3442.	0.8	4
8	The Unknown Unknowns: Recovering Gamma-Delta T Cells for Control of Human Immunodeficiency Virus (HIV). Viruses, 2020, 12, 1455.	3.3	3
9	CD8 T cells targeting adapted epitopes in chronic HIV infection promote dendritic cell maturation and CD4 T cell trans-infection. PLoS Pathogens, 2019, 15, e1007970.	4.7	14
10	Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1. EBioMedicine, 2019, 43, 295-306.	6.1	20
11	Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions. Journal of Virology, 2019, 93, .	3.4	20
12	Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus–Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. Clinical Infectious Diseases, 2018, 67, 1712-1719.	5.8	22
13	Detection of IgC3 antibodies specific to the human immunodeficiency virus type 1 (HIV-1) p24 protein as marker for recently acquired infection. Epidemiology and Infection, 2018, 146, 1293-1300.	2.1	7
14	Development of potent class II transactivator gene delivery systems capable of inducing de novo MHC II expression in human cells, in vitro and ex vivo. Gene Therapy, 2017, 24, 342-352.	4.5	3
15	Novel assay reveals a large, inducible, replication-competent HIV-1 reservoir in resting CD4+ T cells. Nature Medicine, 2017, 23, 885-889.	30.7	68
16	TZA: a novel assay for measuring the latent HIV-1 reservoir. Expert Review of Molecular Diagnostics, 2017, 17, 1033-1035.	3.1	7
17	Tunneling Nanotubes and Gap Junctions–Their Role in Long-Range Intercellular Communication during Development, Health, and Disease Conditions. Frontiers in Molecular Neuroscience, 2017, 10, 333.	2.9	181
18	De Novo Design and Biophysical Characterization of an Affinity-Enhanced Protein Displaying the Structure of the Broadly Neutralizing HIV-1 2F5 Antibody Epitope. Biophysical Journal, 2016, 110, 346a.	0.5	0

ROBBIE B MAILLIARD

#	Article	IF	CITATIONS
19	Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8 + T Cells. MBio, 2016, 7, .	4.1	16
20	Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell–Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti–Programmed Death-1. Journal of Immunology, 2016, 196, 2870-2878.	0.8	19
21	Linked in: immunologic membrane nanotube networks. Journal of Leukocyte Biology, 2016, 100, 81-94.	3.3	30
22	CD40L Induces Functional Tunneling Nanotube Networks Exclusively in Dendritic Cells Programmed by Mediators of Type 1 Immunity. Journal of Immunology, 2015, 194, 1047-1056.	0.8	47
23	Programming T cell Killers for an HIV Cure: Teach the New Dogs New Tricks and Let the Sleeping Dogs Lie. Forum on Immunopathological Diseases and Therapeutics, 2015, 6, 67-77.	0.1	3
24	Baseline Natural Killer and T Cell Populations Correlation with Virologic Outcome after Regimen Simplification to Atazanavir/Ritonavir Alone (ACTG 5201). PLoS ONE, 2014, 9, e95524.	2.5	2
25	The impact of viral evolution and frequency of variant epitopes on primary and memory human immunodeficiency virus type 1-specific CD8+ T cell responses. Virology, 2014, 450-451, 34-48.	2.4	10
26	Dengue virus-infected human dendritic cells reveal hierarchies of naturally expressed novel NS3 CD8 T cell epitopes. Clinical and Experimental Immunology, 2014, 177, 696-702.	2.6	12
27	HIV's Ticket to Ride: Cytotoxic T-Lymphocyte-Activated Dendritic Cells Exploited for Virus Intercellular Transfer. AIDS Research and Human Retroviruses, 2014, 30, 1023-1024.	1.1	2
28	Dendritic Cells Restore CD8 ⁺ T Cell Reactivity to Autologous HIV-1. Journal of Virology, 2014, 88, 9976-9990.	3.4	17
29	Fc Gamma Receptor 3A Polymorphism and Risk for HIV-Associated Cryptococcal Disease. MBio, 2013, 4, e00573-13.	4.1	51
30	Identification of Conserved and HLA Promiscuous DENV3 T-Cell Epitopes. PLoS Neglected Tropical Diseases, 2013, 7, e2497.	3.0	39
31	Selective Induction of CTL Helper Rather Than Killer Activity by Natural Epitope Variants Promotes Dendritic Cell–Mediated HIV-1 Dissemination. Journal of Immunology, 2013, 191, 2570-2580.	0.8	34
32	Safety, Tolerability, and Immunogenicity of Repeated Doses of DermaVir, a Candidate Therapeutic HIV Vaccine, in HIV-Infected Patients Receiving Combination Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 351-359.	2.1	52
33	Naive CD8+ T cells from ART respond to primary vaccination against autologous HIV-1 antigen. Retrovirology, 2012, 9, .	2.0	0
34	Helper Activity of Natural Killer Cells During the Dendritic Cell-mediated Induction of Melanoma-specific Cytotoxic T Cells. Journal of Immunotherapy, 2011, 34, 270-278.	2.4	47
35	Typeâ€1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8 ⁺ T cells against prostate cancer cells and defined prostate cancerâ€specific epitopes. Prostate, 2011, 71, 125-133.	2.3	32
36	A novel ¹⁹ F agent for detection and quantification of human dendritic cells using magnetic resonance imaging. International Journal of Cancer, 2011, 129, 365-373.	5.1	61

ROBBIE B MAILLIARD

#	Article	IF	CITATIONS
37	Dendritic Cells Reveal a Broad Range of MHC Class I Epitopes for HIV-1 in Persons with Suppressed Viral Load on Antiretroviral Therapy. PLoS ONE, 2010, 5, e12936.	2.5	14
38	Independent Regulation of Chemokine Responsiveness and Cytolytic Function versus CD8+ T Cell Expansion by Dendritic Cells. Journal of Immunology, 2010, 184, 591-597.	0.8	64
39	Dendritic cells and NK cells. , 2010, , 239-253.		1
40	Functional assessment of human dendritic cells labeled for in vivo 19F magnetic resonance imaging cell tracking. Cytotherapy, 2010, 12, 238-250.	0.7	87
41	Maturation Pathways of Dendritic Cells Determine TAP1 and TAP2 Levels and Cross-presenting Function. Journal of Immunotherapy, 2009, 32, 465-473.	2.4	37
42	Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. Journal of Leukocyte Biology, 2008, 84, 319-325.	3.3	71
43	Memory CD8+ T Cells Protect Dendritic Cells from CTL Killing. Journal of Immunology, 2008, 180, 3857-3865.	0.8	36
44	Cytolytic cells induce HMGB1 release from melanoma cell lines. Journal of Leukocyte Biology, 2007, 81, 75-83.	3.3	81
45	Helper Function of Memory CD8+ T Cells: Heterologous CD8+ T Cells Support the Induction of Therapeutic Cancer Immunity. Cancer Research, 2007, 67, 10012-10018.	0.9	27
46	Generation of alpha-Type-1 Polarized Dendritic Cells as a Potent Immunogen in Patients with Chronic Lymphocytic Leukemia Blood, 2007, 110, 2059-2059.	1.4	1
47	Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation. Melanoma Research, 2006, 16, 165-174.	1.2	8
48	Helper Roles of NK and CD8 ⁺ T Cells in the Induction of Tumor Immunity Polarized Dendritic Cells as Cancer Vaccines. Immunologic Research, 2006, 36, 137-146.	2.9	56
49	Polarized DC1-Based Therapeutic Cancer Vaccines. Journal of Immunotherapy, 2005, 28, 656.	2.4	2
50	IL-18–induced CD83+CCR7+ NK helper cells. Journal of Experimental Medicine, 2005, 202, 941-953.	8.5	260
51	Natural killer–dendritic cell cross-talk in cancer immunotherapy. Expert Opinion on Biological Therapy, 2005, 5, 1303-1315.	3.1	99
52	Helper role of NK cells during the induction of anticancer responses by dendritic cells. Molecular Immunology, 2005, 42, 535-539.	2.2	98
53	α-Type-1 Polarized Dendritic Cells. Cancer Research, 2004, 64, 5934-5937.	0.9	449
54	Neuroblastoma and dendritic cell function. Seminars in Pediatric Surgery, 2004, 13, 61-71.	1.1	18

ROBBIE B MAILLIARD

#	Article	IF	CITATIONS
55	Alpha-Type-1-Polarized DC (αDC1): DC-Based Vaccines with Optimized Anti-Cancer Activity. Journal of Immunotherapy, 2004, 27, S24.	2.4	0
56	NK Cell "Help" Boosts the Efficacy of Anti-Melanoma Immunotherapy: Development of a Clinically Applicable DC1NK-Based Vaccine. Journal of Immunotherapy, 2004, 27, S27.	2.4	0
57	Type 1 Polarized Dendritic Cells as Superior Therapeutic Vaccines Against Melanoma. Journal of Immunotherapy, 2004, 27, S22.	2.4	Ο
58	Advanced neuroblastoma impairs dendritic cell function in adoptive immunotherapy. Journal of Pediatric Surgery, 2003, 38, 857-862.	1.6	12
59	Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo. Journal of Pediatric Surgery, 2003, 38, 301-307.	1.6	19
60	Dendritic Cells Mediate NK Cell Help for Th1 and CTL Responses: Two-Signal Requirement for the Induction of NK Cell Helper Function. Journal of Immunology, 2003, 171, 2366-2373.	0.8	326
61	Complementary Dendritic Cell–activating Function of CD8+ and CD4+ T Cells. Journal of Experimental Medicine, 2002, 195, 473-483.	8.5	167
62	Differential regulation of maturation and apoptosis of human monocyte-derived dendritic cells mediated by MHC class II. International Immunology, 2002, 14, 1027-1037.	4.0	26
63	Dendritic Cells Pulsed With Apoptotic Squamous Cell Carcinoma Have Anti-Tumor Effects When Combined With Interleukin-2. Laryngoscope, 2001, 111, 1472-1478.	2.0	15
64	Interleukin-18 markedly augments NK cell proliferation and cytotoxicity when combined with low-dose interleukin-2. Journal of the American College of Surgeons, 2000, 191, S16.	0.5	0
65	Peripheral blood monocytes derived dendritic cells generated with interferon- \hat{I}_{\pm} and granulocyte-macrophage colony-stimulating factor are potent IL-12 producers. Journal of the American College of Surgeons, 2000, 191, S19.	0.5	Ο
66	Dendritic Cells Promote T-cell Survival or Death Depending Upon Their Maturation State and Presentation of Antigen. Immunological Investigations, 2000, 29, 177-185.	2.0	17
67	MAJOR PHENOTYPIC, MORPHOLOGIC AND FUNCTIONAL DIFFERENCES BETWEEN DCs STIMULATED WITH MONOCYTE-CONDITION MEDIUM OR CYTOKINE COCKTAIL. Journal of Immunotherapy, 1999, 22, 461.	2.4	0